Addition of daratumumab to VRd results in improved progression-free survival for transplantation-eligible patients<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 13, 2023 (HealthDay News) — For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival. These findings were published online Dec. 12 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in San Diego.<\/p>\n Pieter Sonneveld, M.D., Ph.D., from the Erasmus MC Cancer Institute in Rotterdam, Netherlands, and colleagues randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive D-VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group) in a phase 3 trial.<\/p>\n The researchers found that the risk for disease progression or death was lower in the D-VRd group than in the VRd group at a median follow-up of 47.5 months. The estimated percentage of patients with progression-free survival was 84.3 and 67.7 percent in the D-VRd and VRd groups, respectively, at 48 months (hazard ratio for disease progression or death, 0.42). The D-VRd group had a higher percentage of patients with a complete response or better (87.9 versus 70.1 percent) and a higher percentage of patients with minimal residual disease-negative status (75.2 versus 47.5 percent).<\/p>\n “These results further strengthen the existing evidence supporting the use of daratumumab in combination regimens for patients with newly diagnosed multiple myeloma,” the authors write.<\/p>\n The study was partially funded by Janssen Research and Development, the manufacturer of daratumumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n